Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

Phase 2 Unknown 381 enrolled HK inno.N Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This exploratory study is designed to compare safety and efficacy between a Tegoprazan dose-specific standard triple therapy and Lansoprazole standard triple therapy in H. pylori positive patients.

Timeline

Start: 2023-02-27
Primary completion: 2024-12-31
Completion: 2024-12-31

Publications

Park JY, Hong SJ, Choi IJ, Baik GH, Kim SM, Park JJ, Jeon SW, Kim KO, Lee SK, Jung HY, Oh JH, Park CH, Kim SW, Shim KN, Jee SR, Moon HS, Moon JS, Choi CW, Lee WS, Kim JG. Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. Helicobacter. 2026 Jan-Feb;31(1):e70106. doi: 10.1111/hel.70106.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Lansoprazole	Other / unclassified	30 mg	Oral
Subject	Tegoprazan	Other / unclassified	50 mg	Oral
Subject	Tegoprazan	Other / unclassified	100 mg	Oral
Comparator	Amoxicillin	Other / unclassified	1000 mg	Oral
Comparator	Clarithromycin	Small molecule	500 mg	Oral

Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

Summary

Timeline

Publications

Drugs

Indications